Hematologic Oncology | Specialty

Memory-Like Natural Killer Cells for Patients With Advanced AML and MDS

October 26th 2015

Acute myeloid leukemia and myelodysplastic syndromes are the two most common hematologic malignancies of the myeloid lineage origin and both are more common in older patients.

Breakthrough Designation in ALL, HIFU FDA Approval, Breast Cancer Screening Update, and More

October 23rd 2015

FDA Grants Inotuzumab Ozogamicin Breakthrough Status for ALL

October 19th 2015

The FDA has granted the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin a breakthrough therapy designation as a potential treatment for acute lymphoblastic leukemia.

Dr. Nazha on Mutational Model to Predict Response to Hypomethylating Agents in MDS

October 7th 2015

Aziz Nazha, MD, hematologist, Leukemia Program at the Cleveland Clinic, Taussig Cancer Institute, discusses results of a mutational model to predict response to hypomethylating agents in myelodysplastic syndromes (MDS).

Guadecitabine Granted Orphan Designation for AML

October 6th 2015

The FDA has granted an orphan drug designation to the next-generation hypomethylating agent guadecitabine as a potential treatment for patients with acute myeloid leukemia.

Enthusiasm, Questions for Immune Checkpoint Blockade in Lymphoid Diseases

September 23rd 2015

Limited clinical evaluation suggests a potentially major role for immune checkpoint inhibition in the treatment of lymphomas, but early success has also raised many questions.

Molecular Profiling May Hold Key to More Effective Therapy for AML

September 18th 2015

Molecular profiling of every patient with acute myelogenous leukemia may hold the key to better treatment in the future.

Age, Health, Risk Define Treatment Groups and Options in CLL

September 18th 2015

Fitness, age, and disease risk status form the basis for decision-making about first-line therapy for chronic lymphocytic leukemia.

Dr. Carraway on Aza-Nucleoside Combinations in MDS

September 18th 2015

Hetty Carraway, MD, Hematology and Oncology, Cleveland Clinic, discusses combination epigenetic therapies including aza-nucleosides and histone deacetylase inhibitors, as well as immunomodulatory therapies, such as lenalidomide for the treatment of myelodysplastic syndromes (MDS).

FDA Approval Sought for Frontline Ibrutinib in CLL

September 14th 2015

A supplemental new drug application has been submitted for the BTK inhibitor ibrutinib (Imbruvica) as a therapy for treatment-naive patients with chronic lymphocytic leukemia who are over the age of 65.

Chimeric Antigen Receptor Pioneer Sees Solid Tumor Potential

August 26th 2015

A Giant of Cancer Care anticipates that CAR therapy will be beneficial not only in hematologic cancers, where it has proved effective, but also in solid tumors.

Obinutuzumab's Benefit in iNHL Unclear After GAUSS Results Published

August 24th 2015

The anti-CD20 agent obinutuzumab improved overall response and had acceptable toxicity compared with rituximab in patients with relapsed indolent non-Hodgkin Lymphoma, according to the final results from the GAUSS study.

Nowakowski Responds to Phase II Study Criticism and Discusses Future of R2-CHOP in DLBCL

August 24th 2015

Grzegorz S. Nowakowski, MD, responds to questions raised regarding the use of immunohistochemistry in his phase II study, as well as future plans for the investigation of R2-CHOP in non-GCB DLBCL.

Why I Chose a Career in Hematology & Oncology

August 21st 2015

My path to becoming an oncologist was a little different from most, but like so many others, I was inspired by a practicing physician who showed me what medicine truly can be.

FDA Expands Brentuximab Vedotin's Hodgkin Lymphoma Label

August 18th 2015

The FDA has approved the antibody-drug conjugate brentuximab vedotin as a consolidation therapy following autologous stem cell transplantation in patients with Hodgkin lymphoma who are at risk of relapse or progression.

Medicare's Blinatumomab Decision, CHAARTED Data Published, New Immuno-Oncology Collaborations, and More

August 14th 2015

Researcher Responsible for CLL Breakthroughs Honored by ASH

July 31st 2015

John C. Byrd, MD, discusses receiving the American Society of Hematology's 2015 William Dameshek Prize for his numerous therapeutic breakthroughs in chronic lymphocytic leukemia, his impactful career, and his goals for the future.

Ibrutinib Induces Impressive Response in DLBCL Subtype

July 30th 2015

Ibrutinib had an overall response rate of 37% in patients with activated B-cell-like diffuse large B-cell lymphoma.

Idelalisib Use Expands With New CLL Indication Pending

July 30th 2015

The utilization of idelalisib increased substantially between the first and second quarters of 2015, representing promising growth in a highly competitive setting.

Gender Disparities and Other DLBCL Developments

July 28th 2015

Tahir Latif, MD, discusses results of a recent study which found that men may have a lower rate of survival among patients with diffuse large B-cell lymphoma.